Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Show more...
CEO
Blaise Coleman
직원
2931
국가
IE
ISIN
IE00BJ3V9050
WKN
000A1XE6M
상장
0 Comments
생각을 공유하기
FAQ
오늘 Endo International 주가는 얼마인가요?▼
ENDPQ의 현재 가격은 $0 USD이며, 지난 24시간 동안 +0% 상승했습니다. 차트에서 Endo International 주가 흐름을 더 자세히 살펴보세요.
Endo International의 주식 심볼은 무엇인가요?▼
거래소에 따라 주식 심볼이 다를 수 있습니다. 예를 들어, 거래소에서는 Endo International 주식이 ENDPQ 심볼로 거래됩니다.
Endo International의 지난해 매출은 얼마였나요?▼
Endo International의 지난해 매출은 2.01BUSD입니다.
Endo International의 지난해 순이익은 얼마였나요?▼
ENDPQ의 지난해 순이익은 -2.45BUSD입니다.
Endo International에는 직원이 몇 명 있나요?▼
4월 01, 2026 기준으로 회사는 2,931명의 직원을 보유하고 있습니다.
Endo International는 어떤 섹터에 속해 있나요?▼
Endo International는 Professional, Scientific, and Technical Services 부문에서 운영됩니다.